Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc > Levesque was awarded 405 000$ bonus for 2023 representing
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(107)
•••
Comment by Trogarzonon Mar 12, 2024 2:21pm
72 Views
Post# 35928892

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Levesque was awarded 405 000$ bonus for 2023 representing

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Levesque was awarded 405 000$ bonus for 2023 representing To get a break we need to see no additional shoe dropping that could have explainned the KPMG guy leaving.  Anything that shows he did'nt leave because management was too agrissive in their forecast or not disclosing material information.  God knows if we ever know why so in the mean time it's freefall time again.  May is pretty close to get shareholder in such a bad mood.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities